Recently, Novo Nordisk officially released its 2022 financial report. Data shows that Novo Nordisk's total sales in 2022 will reach 176.954 billion Danish krone (US $24.994 billion, the exchange rate conversion announced in the annual report, the same below), up 26% year on year, operating profit will reach 74.809 billion Danish krone (US $10.566 billion), up 28% year on year, and net profit will be 55.525 billion Danish krone (US $7.843 billion), up 16% year on year. The performance is very impressive.

Where does Novo Nordisk's outstanding performance come from? The answer is GLP-1 analogue. In Novo Nordisk's product pipeline, products can be divided into four types: GLP-1 analogues, insulin and analogues, coagulation factors and other metabolic hormones, with sales of 83.371 billion Danish krone ($11.176 billion, excluding weight loss needles), 52.952 billion Danish krone ($7.479 billion), 11.706 billion Danish krone ($1.653 billion) and 7.138 billion Danish krone ($1.008 billion), respectively. Among GLP-1 analogues, the sales of Liraglutide hypoglycemic injection have been declining year by year, while Semaglutide is extremely eye-catching, with a total sales of 10.882 billion dollars in 2022.